EUnetHTA 21 Publication of Second Joint Clinical Assessment: Introducing the Evoke Spinal Cord Stimulation

By Staff Writer

July 21, 2023

 EUnetHTA 21 has published their second Joint Clinical Assessment on the Evoke Spinal Cord Stimulation (SCS) System. This advanced device utilizes Evoked Compound Action Potentials (ECAPs) to guide programming of stimulation parameters and provide real-time, closed-loop stimulation. This unique feature allows the Evoke System to adjust the stimulation output level for every pulse, maintaining the ECAP near the target amplitude. This stands in contrast to other commercially available SCS devices which do not employ spinal cord feedback to adjust stimulation. 

The Evoke SCS is indicated for the treatment of chronic, intractable pain in the trunk and/or limbs. Chronic pain, unlike acute pain, persists long after the initial injury or illness has healed. The Evoke System is primarily used to treat chronic neuropathic, mixed neuropathic/nociceptive, or ischemic pain, all of which are caused by nervous system damage or dysfunction. 

This system is designed for patients with chronic, intractable pain who are not contraindicated for the system. It represents a new generation of SCS because of its ECAP-guided programming, an enhancement to other available SCS systems. 

Promising study results suggest that the Evoke System is comparable or superior to other treatments reported in literature. Clinical data from prospective investigations of the Evoke System support its safety and performance. The anticipated benefits of the Evoke System outweigh the risks, providing a compelling case for its use in treating chronic, intractable pain.

Reference url

Recent Posts

UK Medicine Payment Rates
      

Revitalizing Innovation: The Impact of UK Medicine Payment Rates

💡 Are the UK’s medicine payment rates stifling innovation in life sciences?

Recent analysis reveals that the staggering 23.5% payment rate for pharmaceuticals is not just limiting NHS spending but also curtailing R&D investments, delaying new drug launches, and threatening workforce stability. If we can lower these rates to below 10%, we could unleash significant growth and restore the UK’s competitive edge in the global life sciences landscape.

Discover the critical insights and recommendations that could reshape the future of healthcare in the UK.

#SyenzaNews #healthcarepolicy #innovation

Blinatumomab benefit assessment
            

Blinatumomab Benefit Assessment for ALL and Health Economics

🚀 How does a groundbreaking therapy change the landscape of acute lymphoblastic leukemia treatment?

The recent benefit assessment of Blinatumomab by the German Federal Joint Committee reveals critical insights into its potential as a consolidation therapy for adults with Philadelphia chromosome-negative B-cell precursor ALL. With its orphan drug status promising automatic benefits, the article explores the implications of its high cost and economic impacts, shedding light on the balance needed between innovation and sustainability in healthcare.

Jump into the full analysis to understand how this could impact clinical practice and health economics.

#SyenzaNews #HealthEconomics #MarketAccess

Enhertu reimbursement analysis
                 

Enhertu Reimbursement Analysis: Navigating Cost-Effectiveness Challenges

💡 How do we balance groundbreaking cancer treatments with budget realities?

The recent analysis by the Dutch Healthcare Institute on Enhertu shines a light on the complexities of integrating innovative therapies for HER2-low metastatic breast cancer into national insurance packages. While the clinical efficacy is evident, the substantial cost implications and demand for steep price reductions bring significant challenges to market access.

Explore the nuances of this vital discussion on clinical effectiveness, economic evaluation, and the future of pricing strategies in oncology.

#SyenzaNews #HealthEconomics #MarketAccess

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.